Live In Play®
Updated: 31-May-24 08:06 ET
AUTL:  Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO   (3.99)
  • The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes
  • 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention
  • Ongoing CAR T persistence was associated with improved event-free survival
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.